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François Dabis2,3 and ANRS 12249 TasP study groupAbstract
Background: Antiretroviral therapy (ART) suppresses HIV viral load in all body compartments and so limits the risk
of HIV transmission. It has been suggested that ART not only contributes to preventing transmission at individual
but potentially also at population level. This trial aims to evaluate the effect of ART initiated immediately after
identification/diagnosis of HIV-infected individuals, regardless of CD4 count, on HIV incidence in the surrounding
population. The primary outcome of the overall trial will be HIV incidence over two years. Secondary outcomes will
include i) socio-behavioural outcomes (acceptability of repeat HIV counselling and testing, treatment acceptance
and linkage to care, sexual partnerships and quality of life); ii) clinical outcomes (mortality and morbidity, retention
into care, adherence to ART, virologic failure and acquired HIV drug resistance), iii) cost-effectiveness of the
intervention. The first phase will specifically focus on the trial’s secondary outcomes.
Methods/design: A cluster-randomised trial in 34 (2 × 17) clusters within a rural area of northern KwaZulu-Natal
(South Africa), covering a total population of 34,000 inhabitants aged 16 years and above, of whom an estimated
27,200 would be HIV-uninfected at start of the trial. The first phase of the trial will include ten (2 × 5) clusters.
Consecutive rounds of home-based HIV testing will be carried out. HIV-infected participants will be followed in
dedicated trial clinics: in intervention clusters, they will be offered immediate ART initiation regardless of CD4 count
and clinical stage; in control clusters they will be offered ART according to national treatment eligibility guidelines
(CD4 <350 cells/μL, World Health Organisation stage 3 or 4 disease or multidrug-resistant/extensively drug-resistant
tuberculosis). Following proof of acceptability and feasibility from the first phase, the trial will be rolled out to
further clusters.
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Discussion: We aim to provide proof-of-principle evidence regarding the effectiveness of Treatment-as-Prevention
in reducing HIV incidence at the population level. Data collected from the participants at home and in the clinics
will inform understanding of socio-behavioural, economic and clinical impacts of the intervention as well as
feasibility and generalizability.
Trial registration: Clinicaltrials.gov: NCT01509508; South African Trial Register: DOH-27-0512-3974.
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Thirty years after the discovery of the HIV, the pandemic
does not show significant signs of abating [1]. HIV
plasma viral load (VL) in the index HIV-infected individ-
ual is the dominant determinant of transmission to others,
as shown in studies of heterosexual couples and mother/
child pairs [2,3]. Antiretroviral therapy (ART) with fully
suppressive antiretroviral (ARV) drug combinations lowers
VL and substantially decreases the risk of transmission.
The recent results from the HPTN 052 trial showed that
ART reduced transmission by 96% in stable heterosexual
couples where one partner was HIV-infected and the other
not, and in which the partners had disclosed their HIV
status to each other [4].
Following on from the HPTN052 trial, recent results
from the annual population-based HIV surveys conducted
in the Hlabisa sub-district, KwaZulu-Natal, South Africa
(in the population immediately adjacent to the trial set-
ting) demonstrated significant reductions in the risk of
acquiring HIV in areas of high ARTcoverage [5]. The study
showed that population-level reductions in the transmis-
sion of HIV can be achieved in nurse-led, devolved, public-
sector programmes in rural sub-Saharan African settings
where complete coverage of therapy under existing treat-
ment guidelines has not yet been attained. However, it is
not yet known what impact could be achieved on HIV
incidence at a population level if ART was given to all
HIV-positive individuals [6].
In 2009, results from a mathematical modelling exercise
using a hypothetical population and assumptions relating
to the South African (SA) setting suggested that ‘universal
voluntary HIV testing and immediate ART (regardless
of CD4 count) combined with present prevention ap-
proaches could have a major effect on severe generalised
HIV epidemics’ [7]. Subsequent modelling confirmed that
the impact of test-and-treat approaches on HIV incidence
depends on the epidemiological context (characteristics
of the sexual partner network, including heterogeneity,
concurrency and mixing; HIV testing uptake; linkage to
care and ART coverage; among others) [8-10]. Earlier
treatment initiation may reduce HIV incidence at a
population level and well-conducted observational studies
have shown that it may likely benefit the individual
[11,12]. While the question of when to start ART is stilla matter of debate worldwide and is the subject of two
ongoing randomised trials - the NIH-sponsored START
trial (clinicaltrials.gov identifier NCT00867048) and the
ANRS-sponsored TEMPRANO trial (clinicaltrials.gov
identifier NCT00495651), recent evidence suggests
long-term benefits of starting ART earlier would likely
be of particular importance in settings where the inci-
dence of life-threatening HIV-related diseases occurring
at relatively high CD4 levels (tuberculosis, invasive bac-
terial diseases, and possibly malaria) is substantial, a
typical situation in most of sub-Saharan Africa includ-
ing SA [13].
We hypothesise that HIV testing of all members of a
community, followed by immediate ART initiation of all
HIV-infected adults regardless of immunological or clinical
staging will reduce onward sexual transmission of HIV and
hence HIV incidence. To test this hypothesis, we designed
a cluster-randomised trial [14] for implementation in
Hlabisa sub-district, KwaZulu-Natal, SA, in a two-phased
approach. Enrolment in the first phase started in 2012,
first in four clusters then in an additional six clusters in
early 2013; if results from the first phase indicate good
acceptability and feasibility, it is expected that the second
phase will then be implemented in the other 24 (2 × 12)
clusters from 2014 to 2016.
Objectives
Main trial objective
The main objective is to evaluate the impact of ART,
initiated immediately after identification/diagnosis of HIV-
infected adults irrespective of CD4 count or clinical staging,
on the incidence of new HIV infections in the general
population over a period of 24 months, in comparison with
treatment initiated according to national eligibility criteria.
Specific trial objectives
The objectives among all participants, to determine
acceptability and feasibility over a 24-month period of
providing repeat HIV testing to adult members of a
community followed with immediate ART for HIV-infected
individuals, and more specifically to compare between the
two arms (intervention versus control) the following:
acceptability and uptake of initial and repeat HIV counsel-
ling and testing; sexual behavioural changes and prevention
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ward HIV-infected individuals and perception of care
and HIV treatment; and household expenditure, cost-
effectiveness and other economic consequences of the
trial at household level.
Among HIV-infected participants, to compare between
the two arms over a 24-month period, the objectives are
to determine: acceptability and uptake of HIV care and
ART provided at the trial clinics; therapeutic success/
effectiveness and tolerability of ART, participant retention
in care, mortality and morbidity, tuberculosis notification
rates, virological treatment failure, acquired HIV drug
resistance and toxicity; adherence to ART; and quality
of life.
Within the health system, the objective is to identify
the challenges faced by the health care system and health
care professionals in providing the trial intervention and
coping with the increased number of trial participants.
The aim of the first phase of the trial
The aim will be to inform the decision-making towards
the implementation of the trial second phase through:
i) the validation and updating of the model parameters
(uptake of HIV testing, linkage to care upon HIV diagnosis,
internal migration and ART initiation) used to estimate
the trial sample size and HIV incidence; ii) assessment
of the acceptability and feasibility of the intervention.
Methods
Study design
This is a cluster-randomised controlled trial planned to take
place over five years (2012 to 2016). The overall trial con-
sists of 34 (2 × 17) clusters divided into two arms, coveringCluster rando
17 Control Clusters
Phase 1: 5 clusters
Component 1: test
HIV testing
Prevention services
Phase 1: 5 000 pers. (4 000 HIV neg.)
Component 2: treat
ARV treatment according to WHO 
guidelines
Maximum 500 HIV pos. individuals. 
Treated within treatment guidelines
Figure 1 Description of the different components of the ANRS 12249a total population of 34,000 eligible inhabitants, of whom
an estimated 27,200 would be HIV-uninfected at trial com-
mencement. In the trial communities HIV testing of all
members will take place at regular intervals (component 1).
The impact of two different ART initiation strategies on
HIV incidence (component 2) will then be compared as
illustrated in Figure 1. During the first phase of the trial,
three consecutive rounds of home-based HIV testing
are implemented in the first four clusters; the duration
of the first calendar round of testing (CR) is six months,
the second and the third CRs are four months. Six-
monthly CR is planned in the subsequent six clusters
and for the rest of the clusters if the second phase is
implemented. Follow up of HIV-infected participants in
trial clinics (one in each cluster) is planned for 24
months in the overall trial, and for a maximum of 20
months during the first phase if the trial does not con-
tinue into the second phase.
Setting
The trial is conducted in Hlabisa sub-district (Figure 2),
Umkhanyakude district, of northern KwaZulu-Natal, SA.
This predominantly rural setting of 1,430 km2 in size has
a population of approximately 220,000 Zulu-speaking
people. In this sub-district, the Africa Centre for Health
and Population studies, a research institute at the University
of KwaZulu-Natal [http://www.africacentre.com] carries
out sociodemographic and HIV surveillance and clinical
research. Estimated HIV prevalence among adults in
Hlabisa sub-district was 20% in 2007 [15], with consid-
erable spatial heterogeneity [16,17]. The crude HIV incidence
rate within the Africa Centre Demographic Surveillance
Area (DSA), an area covering 400 km2 within the sub-misation
17 Intervention Clusters
Phase 1: 5 clusters
Component 1: test
HIV testing
Prevention services
Phase 1: 5 000 pers. (4 000 HIV neg.)
Component 2: treat
Immediate ARV treatment regardless of 
CD4 counts
Maximum 1 000 HIV pos. individuals. 
Treated (500 outside existing 
guidelines)
TasP trial.
Figure 2 ANRS 12249 TasP Trial clusters within Hlabisa sub-district (South Africa).
Iwuji et al. Trials 2013, 14:230 Page 4 of 15
http://www.trialsjournal.com/content/14/1/230district, was estimated at 3.4 per 100 person-years be-
tween 2003 and 2007 [18,19] declining to 2.9 per 100
person-years between 2004 and 2009 [20].
In 2004, the Africa Centre and the KwaZulu-Natal De-
partment of Health (DoH) established the Hlabisa HIV
Treatment and Care Programme, devolved to all 17 pri-
mary health care clinics in the sub-district [21]. HIV testing
is available at all primary health care clinics and the dis-
trict hospital, including mobile clinics regularly offering
testing in communities, mobile testing clinics at com-
munity events, and home-based HIV counselling and
testing (HCT) in households across the sub-district, which
started in 2009 and has proved to be highly acceptable
with a high uptake rate [22]. Comprehensive prevention
services include information and education, condom
promotion and distribution; medical male circumcision;
syndromic management of sexually transmitted infections;
post-exposure prophylaxis after sexual assault; and family
planning. HIV treatment and care is provided free at all pri-
mary health care clinics, with ART eligibility determined
by SA guidelines, which since August 2011 used a CD4
350 cells/μL eligibility cutoff for all adults. By the end of
2011, more than 40,000 individuals had accessed HIV care
in the sub-district and over 20,000 of them had been initi-
ated on ART. The ART coverage within the DSA was esti-
mated at 37% of all HIV-infected adults [5].
Trial participants (inclusion and exclusion criteria)
Individuals are eligible for trial participation if aged 16 years
and above and a member of a household in the designated
cluster (head of household defines membership status inZulu culture). They must be able and willing to give writ-
ten informed consent for trial participation and/or HCT.
Individuals considered unable to provide informed con-
sent will include those with severe uncontrolled psychi-
atric disorders, and those with neurological impairment
resulting in an inability to participate in the informed con-
sent process.
Cluster design
The randomisation units within the TasP trial are geo-
graphic clusters within Hlabisa sub-district, outside of the
Africa Centre DSA [23]. In brief, the trial area consists of
211 local areas (neighbourhoods). Clusters were designed
to encompass social and sexual networks based on earlier
studies in the DSA [24] with the aim of keeping the poten-
tial for cross-arm contamination to a minimum. The 211
local areas were thus aggregated into 48 clusters of be-
tween one and six contiguous neighbourhoods, compris-
ing an average of 1,000 individuals aged 16 years and
above and having a median area of 19 km2.
From a statistical efficiency perspective (smallest sample
size) more clusters of fewer people should be used. How-
ever, having very small units of randomisation would
result in greater potential for contamination. Adjacent
neighbourhoods have thus been combined with this
trade-off between statistical efficiency and contamination
potential in mind in order to form relatively large ran-
domisation units (with similar numbers of participants)
with a distinct social identity. This reduces the risk of con-
tamination whilst still retaining a relatively large number
of clusters for the trial (Figure 2).
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We used two independent well-established mathematical
models, the cost-effectiveness of preventing AIDS com-
plications (CEPAC) [25], and a microsimulation model
for decision support in sexually transmitted disease con-
trol (STDSIM) [26]) to demonstrate that a 30% reduc-
tion in cumulative HIV incidence (5% versus 3.5%) in
HIV-negative participants over two years would be feas-
ible across a range of parameter space. The models as-
sumed that 10% of individuals in the trial would select a
partner from a community randomised to the opposite
arm of the trial. Sample size calculations indicated that
34 clusters (17 in each arm), with 1,000 consenting par-
ticipants 16 years or older in each cluster (n = 34,000;
27,200 HIV-negative), were required to achieve this ob-
jective. This sample size has 88% power to detect this
difference, with an alpha-type-one error of 5% (two-
tailed) and an allowance of 20% of HIV-negative partici-
pants lost to follow up for the primary outcome measure.
We assumed a coefficient of variation of 0.25 to account
for within-group variation between clusters, the value
of which was based on the values used in other ran-
domised trials in Africa with HIV incidence as the
outcome measure [27]. The cluster size variability cor-
rection was not included in the calculation because
the clusters were designed to be of approximately
equal population size.
The first phase is conducted on approximately 10,000
participants in 10 clusters. This sample size allows the
measurement of the proportion agreeing to test over
three rounds of home-based HIV testing to within 1%
(95% CI).
Randomisation
Randomisation was performed by the trial statisticians
before the start of the first phase. Communities were
randomly allocated in equal measure to control and inter-
vention communities (17:17). To minimise the degree of
between-cluster variation, communities were stratified on
the basis of predicted HIV prevalence, using HIV surveil-
lance data from the Africa Centre’s DSA and data from
antenatal clinics (six strata). Random number generation
and the randomisation procedure were performed in
MapInfo version 11.0. Randomisation was carried out
within each stratum to derive an equal number of con-
trol and intervention communities per stratum.
Contamination minimisation
An important component of trial design has been the
minimisation of contamination and the extent to which
individuals will select their partner from an area randomised
to the opposite arm of the trial. We have previously shown
that partner choice in this population has a strong local
geographical dimension [28]. As stated above, we allowedfor 10% of individuals to have a partner from an area
randomised to the opposite arm of the trial. In addition,
in the randomisation, chance geographical groupings of
communities randomised to the same arm of the trial
occur and thus super-clusters are formed. In multiple
simulations we showed that these super-clusters have a
median population size of approximately 4,000. Given
the well-documented geography of sexual partner choice
in this population [28], these larger chance geographical
groupings of clusters randomised to the same arm of the
trial further reduce the potential for inter-arm contamin-
ation in the trial.
Another source of contamination, arguably more likely,
refers to HIV-infected individuals within a control cluster
breaking the assignment and seeking ART in an inter-
vention cluster. We contain the threat of this type of
contamination because only people registered through
the household HCT as being eligible for immediate ART
initiation will be able to do so within the trial, and data
collection always starts in the household. To be initiated
on ART at the trial clinic, individuals have to present
their TasP card (given to them during the home-based
HIV testing) and South African identity card to the clinic
staff, who confirm from the netbook registration (as de-
scribed below) whether or not a person is resident in an
intervention cluster.
For the pilot phase, the initial four (2 × 2) clusters were
selected on the basis of proximity to the Africa Centre.
The pilot clusters all contain similar rural populations.
In addition, each cluster pair (intervention/control) con-
tained a local department of health clinic. The additional
six (3 × 2) clusters were chosen to be contiguous to these
initial four clusters.
Study procedures
Home-based procedures
In 1999 (as part of the establishment of the Africa Centre)
all homesteads in the Hlabisa sub-district were mapped
and assigned an external bounded structure identification
number (BSID), with details of the head of household at
the time also recorded. Before the start of the TasP trial,
these maps were compared with a recent satellite image
of the sub-district, which allowed the Africa Centre geo-
graphic information system team to map homesteads newly
constructed after 1999, before TasP trial fieldwork com-
mences in any given cluster. Each fieldworker/counsellor
carries a netbook with global positioning system (GPS)
functionality and a map of the trial clusters showing a
satellite image of the various homesteads and their BSIDs
as well as the cluster boundaries. These netbooks are also
equipped with software created at the Africa Centre for
registering/processing homesteads and household mem-
bers. The fieldworkers identify homesteads using the
GPS function in the netbook, and seek permission from
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enumerate all eligible members within the household,
with specific information sheets for all individuals. A
private space is identified and all individual adult house-
hold members are invited to give written permission to
1) complete an individual questionnaire, with or without
anonymous sampling of blood for HIV surveillance,
and/or 2) undergo confidential HCT. People who do
not want to be tested for HIV in the household are in-
formed they can attend any of the local clinics or the
trial clinic for testing. Participants who give consent to
anonymous HIV surveillance have blood collected by
field workers by finger prick and stored on filter paper
as dried blood spots (DBS) - DBS are stored at the
Africa Centre virology laboratory in Durban. Basic demo-
graphic data are obtained from the household head for
participants who decline both HCT and completion of the
questionnaires. The same procedure applies in subsequent
rounds of HIV testing.HCT procedures and prevention services
HIV testing services provided in both trial arms consist
of the current range of community and clinic testing op-
tions plus the implementation of regular rounds of home-
based HIV testing, to achieve near-universal HIV testing
coverage in the area and increase repeat HIV testing. Dur-
ing each HIV testing round, individuals providing written
informed consent for HIV counselling and testing receive
pre-test HIV counselling privately and confidentially,
delivered by a trained counsellor. Rapid HIV testing is
performed and test results are provided approximately
20 minutes after testing. The HIV status of the partici-
pant is documented in the fieldworkers’ netbooks.
The individual post-test HIV counselling session takes
place as per routine DoH procedures, covering the pre-
vention of acquisition of HIV for HIV-negative people
and the implications of HIV infection for HIV-positive
people. All participants have access to all available HIV
prevention services in the routine health care system and
these are also available at the trial clinics.
At the end of each working day, all fieldwork netbooks
are handed to the Data and Specimen coordinator at the
Africa Centre who synchronises the information from
the netbooks to the main database. The information in
the database is subsequently downloaded to all the netbooks
used in the field, as well as in the clinics (see below). Hence,
the netbooks come in from the field with information
from different participants but leave the Africa Centre with
identical information on all participants that have ever been
registered in the trial and their trial status. This data syn-
chronisation process makes it possible for the counsellor
in the trial clinic to know exactly why someone bearing
the TasP card attends the clinic.Referral procedures to trial clinic
At the end of the HCT session, all participants are given
a TasP referral/prevention card containing information
about the trial clinics and the available services. Each
participant is asked to take their TasP card with them
when they attend the trial clinics, to identify them as a
trial participant. A fingerprint is taken at the clinic dur-
ing a participant’s first visit and confirmed at subsequent
visits for correct identification and service eligibility (that
is, treatment and care, prevention or HCT). Results from
the clinic baseline VL test confirm HIV-positive status,
except for individuals already established on ART. Where
there is discrepancy in results between the VL test and the
rapid antibody test, the DBS from the home-based testing
stored in the Africa Centre virology laboratory can be
accessed for confirmatory antibody testing.
Although all HIV-positive individuals (newly diagnosed
and those with known positive status) identified by the
fieldworkers are referred to the trial clinics, those who
know their HIV status and are already in care have the
option of continuing to receive care and treatment with
their existing provider; they are invited to attend for
review at the trial facility every six months to record
clinical outcome data relating to the secondary outcomes.
There is also ethics approval to link the Hlabisa HIV
Treatment and Care Programme database (ARTemis)
maintained by the Africa Centre with that of the trial
database (also held and maintained at the Centre) using
a participant’s unique South African identification num-
ber or name, if both first and last name matched, to
obtain a more complete picture of linkage to care and
treatment data of participants enrolled in the trial but
opting to continue their HIV care with their current
provider.
Participants who are not linked to care within three
months of referral are followed up with a phone call and
if necessary a repeat home visit is performed by a tracker
to explore barriers to linkage as well as to support the
participant in engaging with care.
Procedures for the management and care of
HIV-infected participants
Trial clinics (one per cluster) are situated in close prox-
imity to homesteads (<45 minutes walking distance for
all participants within the cluster). These trial clinics are
staffed by a counsellor and a nurse. A trial physician is
available weekly at each clinic and on call at other times.
Baseline clinic visit
All participants identified as HIV-infected during any of
the home-based HCT rounds are referred to their trial
clinic for immediate assessment (within two weeks of
diagnosis or as soon as feasible thereafter). The partici-
pants present their TasP card to the clinic team who
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ensure they had completed the household procedures
and they are from the appropriate cluster. They are
provided standard counselling/ART education and ad-
herence sessions by the ART counsellor and nurse, over
one to three visits, as per DoH guidelines. They are asked
to provide written consent to: 1) provide self-reported
information and blood specimens for VL testing and
2) receive care and/or treatment at the trial clinics as
per local DoH standards.
All HIV-infected participants consenting to treatment
undergo clinical evaluation (Table 1) and in addition a
CD4 point of care assessment (using Alere PIMA™ de-
vice tool, Alere Inc., Waltham, MA, USA). Patients are
also interviewed by the counsellor on their HIV testing
experience, ART perception, disclosure and economic
situations.
All participants eligible for ART are seen within two
weeks of this baseline visit, to review results of baseline
investigation and, if indicated, initiate treatment as fol-
lows. In the intervention clusters, all HIV-infected par-
ticipants are eligible for ART regardless of CD4 count
and clinical stage. In the control clusters, HIV-infected
participants are eligible for ART as per the 2011 SA and
2010 WHO guidelines [29]: CD4 count ≤350 cells/mm3
irrespective of clinical symptoms; WHO clinical stage 3
or 4 irrespective of CD4 count; and multidrug-resistant
(MDR) or extensively drug-resistant (XDR) tuberculosis.
In the control clusters, patients not yet eligible for ART
have a blood sample collected for baseline VL measure-
ment and storage at the Africa Centre virology labora-
tory; they are invited to return to the study clinic in 4 to
6 months for repeat clinical assessment and CD4 count
measurement (Table 2).
In both clusters, patients declining ART are asked to
consent to 6-monthly clinical assessment. Also in both
clusters, participants already established on ART in the
Hlabisa HIV Treatment and Care Programme (or any
other public or private care provider) are encouraged to
transfer their care to the trial clinics. Participants choosing
to continue follow up from their normal provider are
asked to consent to 6-monthly reviews and to provide per-
mission for additional clinical information obtained from
their provider to be used in the trial.
ART initiation visits and ARV drugs used within the trial
ART initiation takes place at month 0 (M0), ideally within
four weeks of HIV testing or two weeks of enrolment at
the trial clinic, unless purposely delayed for clinical rea-
sons (for example, tuberculosis treatment). Once the de-
cision to initiate ART has been made, patients receive
ART and are followed up as long as the trial first phase
continues and for a minimum of 24 months within the
overall trial.All ART drugs used in the trial are included in those
recommended by the South African National Depart-
ment of Health Adult HIV management guidelines. The
standard first-line drug regimen for HIV-infected partici-
pants in both arms is the fixed drug combination (FDC)
tenofovir (TDF 245 mg) + emtricitabine (FTC 200 mg) +
efavirenz (EFV 600 mg) formulated as Atripla® (dose one
tablet once daily). Use of other regimens is according to
clinical indication [14].
Patient follow up
Participants receiving ART undergo monthly clinical evalu-
ation as described in Table 1. Participants who are not on
ART (not yet eligible for treatment or declining treatment)
are referred to the trial nurse for pre-ART care, positive
prevention services and 6-monthly clinical assessments
(Table 2). Participants on ART who prefer to remain
within the Hlabisa HIV Treatment and Care Programme
are asked to consent to assessment by the trial nurse as
per trial protocol (a trial nurse attends each of the DoH
clinics once a week). The relevant data are collected from
all clinic attendees irrespective of ART status, to complete
the trial case report forms (CRFs). All participants followed
in the trial clinics also complete a follow-up questionnaire
administered by an independent interviewer to assess,
among others, evolving perceptions of ART, stigma and
discrimination, self-reported adherence, quality of life and
health expenditure.
Participants missing a trial clinic appointment are phoned,
and if contacted a new appointment is scheduled taking
into account their drug supply. The names and details
of those not reached are handed over to a tracker for
tracing. One of the consent forms signed by the partici-
pants allows a member of the trial team to track them
should they default. This is also the standard of care in
the Hlabisa HIV Treatment and Care Programme. Par-
ticipants are allowed to exit the clinic if they migrate
out of the clusters but can attend another trial clinic if
migration is to another cluster within the same arm of
the trial. Those who migrate out of the clusters can also
rejoin the trial clinic if they move back into the trial
clusters.
Toxicity (adverse events) and treatment failure
In the case of toxicity or intolerance, single drug sub-
stitutions are allowed, as per SA guidelines [30]. The
toxicities specifically monitored include renal dysfunc-
tion (TDF), liver function (nevirapine - NVP), and anaemia
(zidovudine - AZT).
Routine virological monitoring occurs at 3 and 6 months,
and then 6-monthly during follow up. The decision to
switch to second-line ART is taken on the basis of two
consecutive HIV VL measurements >1,000 copies/mL
at least three months apart (as per current SA national
Table 1 Follow-up calendar for HIV-infected participants eligible for ART
D0/D15 M0 M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 M18 M19 M20 M21 M22 M23 M24
Consent X
Medical history X
Nurse
Physical examination X X X X X X X X X X X X X X X X X X X X X X X X
Weight, height X X X X X X X X X
WHO clinical staging X X X X X X X X X X X X X X X X X X X X X X X X
Morbidity/hospitalisation X X X X X X X X X X X X X X X X X X X X X X X X
TB/STI screening if appropriate X X X X X X X X X X X X X X X X X X X X X X X X
CD4 point of care X X X X X
ART initation X X X X X
Adherence monitoring X X X X X X X X X X X X X X X X X X X X X X X
Laboratory
HIV VL X X X X X X
Genotyping As clinically indicated, in case of confirmed virological failure
CD4 counts X X X X X
Haematology X X X X X
Biochemistry X X X X X X
HBsAg X
Beta hCG X X X X X X
Urinalysis X X X X X X
Plasma storage (−80°C) X X X X X X
Blood volume (mL)
Questionnaires
History of HIV infection X
ART perception X
ART knowledge X X X X X
Disclosure and couple X X X X X X X X
Social and community support X X X X X X X X X
Stigma and discrimination X X X X X
Self-reported adherence X X X X X X X X
Health expenditure X X X X X X X X X
Economic situation X X X X X X X X X
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Table 1 Follow-up calendar for HIV-infected participants eligible for ART (Continued)
Sexual behaviour X X X X X X X X X
Quality of life X X X X
Satisfaction with care X X X X
ANRS 12249 TasP trial, WHO World Health Organisation, TB Tuberculosis, STI Sexually transmitted infections, ART Anti-retroviral treatment, VL Viral load, HBsAg Hepatitis B surface antigen, Beta hCG Beta human
chorionic gonadotrophin.
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Table 2 Follow-up calendar of HIV-infected participants
not eligible for ART
Month
0 6 12 18 24
Consent x
Medical history x
Nurse
Physical examination x x x x x
Weight, height x x x x x
WHO clinical staging x x x x x
Morbidity/hospitalisation x x x x x
TB/STI screening if appropriate x x x x x
CD4 point of care x x x x x
Laboratory
Beta human chorionic gonadotropin x x x x x
Clinic-based survey
ART perception x
ART knowledge x x x x x
Disclosure and couple x x x x x
Social and community support x x x x x
Stigma and discrimination x x x x x
Health expenditure x x x x x
Economic situation x x x x x
Sexual behaviour x x x x
Depression and Anxiety x x x x
HIV quality of life x x x x
Satisfaction with care x x x x
ANRS 12249 TasP trial. WHO World Health Organisation, TB Tuberculosis, STI
Sexually transmitted infections, ART Anti-retroviral treatment, VL Viral load.
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made available in real time to the trial clinician to guide
the decision whether to switch regimens. The standard
second-line regimen is zidovudine (AZT) + lamivudine
(3TC) + lopinavir/ritonavir (LPV/r). Participants positive
for hepatitis B surface antigen (HBsAg) continue TDF in
their ART regimen should they need to switch to second-
line therapy. Trial participants fulfilling criteria for im-
munological and/or clinical failure in the absence of
criteria for virological failure are reviewed by the trial
clinician before any switch in drug regimen.
Care of patients at the end of the trial
Trial participants receiving ART at the end of the trial will
be transferred into the Hlabisa HIV Treatment and Care
Programme and will remain on the same drugs. The
drugs will then be provided by the KwaZulu-Natal DoH,
whether first-line or second-line drug regimens.
Concomitant therapies
Isoniazid preventive therapy, cotrimoxazole and multivi-
tamins are provided to HIV-infected participants in theintervention and control clusters as per national policies
at the time of the trial.Data collection tools
A combination of quantitative and qualitative trial in-
struments are used (Table 1) [14]. Home-based question-
naires will be completed at household level: head of
households are interviewed on household assets, house-
hold income, food security. Home-based questionnaires
are also completed at individual level, for all participants
(core questions repeated at each round and a set of
additional questions specific to certain rounds): individual-
level social and demographic characteristics, HIV testing
behaviour, sexual behaviour, prevention behaviours adopted
(condom use, circumcision status), partnerships and sexual
network patterns, attitudes and beliefs about HIV infec-
tion, HIV testing and treatment, stigma and disclosure,
healthcare use and healthcare expenditures, and quality
of life.
CRFs are completed by the counsellors at baseline and
follow up, and a combined history and clinical examin-
ation CRF is completed by the research nurses, for all
HIV-infected participants receiving care and treatment
in the trials clinics irrespective of their ART status at en-
rolment into the trial and during follow up. A clinic-
based survey will be performed for HIV-infected patients
followed up at the trial clinics: testing experience (base-
line only), ART knowledge, ART perception and decision,
disclosure, sexual partnership details, sexual behaviour,
self-reported ART adherence, HIV quality of life, stigma
and discrimination, social and community support, eco-
nomic and social outcomes, health expenditures, and
satisfaction with care.
Clinic activity reports will be completed: monthly ac-
tivity records of the trial clinics, patient waiting times,
staffing levels, stock outage, the adequacy of trial logis-
tics and support. Qualitative data will be collected to
address the acceptability of repeat testing, adherence
and quality of life among those starting treatment in the
trial clinics: consumer advisory panels in each of the four
original clusters to monitor the community experiences
of the trial, perceptions and understanding of the inter-
vention and early advice on any possible problems.
Repeat in-depth interviews will be performed to explore
the adherence and quality of life in HIV-infected partici-
pants initiating ART in the trial clinics.Trial outcomes
Primary outcome
The primary outcome is HIV incidence measured at
24 months through repeat longitudinal HIV testing of
blood samples collected on DBS during the home visits.
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Among all participants The acceptability and uptake of
HIV testing will be assessed as the proportion of partici-
pants who are tested for HIV among all those eligible,
among those never tested and among those testing HIV-
negative at the first round and who accept repeat HIV
testing. We will also assess the proportion of participants
who know their HIV status and who disclose their HIV
status. These outcomes will be calculated for each succes-
sive round of home-based HIV testing and will be based
on data collected during the home visits. HIV testing
history outside the trial, and perception about repeat
HIV-testing will also be studied.
Behavioural changes at individual level will be studied
through the number of sexual partnerships, prevention
behaviours adopted (for example, condom use and HIV
testing outside the trial, circumcision, contraceptive use)
and attitudes towards HIV-infected individuals. These data
will be collected from all enumerated participants during
successive rounds of home-based testing. This will facilitate
longitudinal as well as repeat cross-sectional analyses
regardless of participants’ self-reported HIV status.
Individual perceptions of community awareness, and
individual attitudes and behaviours towards HIV, repeat
HIV testing and ART will be measured during the suc-
cessive rounds of home-based testing.
Cost-effectiveness analysis, assessing the number of life
years gained and the number of quality-adjusted life years
(QALYs) saved, will be carried out based on data from
the TasP trial and will be completed with a mathemat-
ical Markov model, comparing treatment initiation as
soon as HIV infection is diagnosed to delayed treatment
initiation according to WHO recommendations.
Among HIV-infected participants
The following outcomes will be measured for participants
newly diagnosed with HIV infection and those known to
be infected but not receiving ART.
Acceptability and uptake of care and ART will be
assessed using time from receipt of HIV test result to
enrolment at the trial clinics or primary health care
clinics, transfer of care of patients currently being moni-
tored (as yet ineligible for ART) in the primary health
care clinics to the trial clinics; characterisation of the
population entering into treatment and care and evolu-
tion of the social factors that facilitate entry (for example,
household composition, social support, disclosure to
family, treatment knowledge). All of these intermediate
measures will be useful in determining the need and
content of any special interventions to support treat-
ment uptake in the main trial.
The therapeutic success and evaluation of ART will be
estimated as the proportion of HIV-infected participants(ART-naïve at enrolment) with VL <50 copies/mL after
six months of ART.
Additional secondary outcomes will be explored in all
HIV-infected participants including those already receiv-
ing ART at enrolment as follows. Retention in care,
defined as those still under active follow up in the trial,
will be assessed at 12 months and 24 months post-
enrolment. Loss to follow-up on ART will be defined
as ≥3 consecutive missed appointments. For those not
eligible for ART, loss to follow-up in control clusters
will be defined as >9 months from last clinic visit and/or
CD4 cell count. Mortality, severe morbidity including
WHO stage IV disease, serious non-AIDS events, tuber-
culosis and grade 3 and 4 adverse events (clinical and la-
boratory) will be documented. Virological failure will be
defined as two consecutive VL >1,000 copies/mL mea-
sured 3 months apart. Adherence will be measured using
1) a scale that has already been translated and validated by
Africa Centre researchers with patients from the Hlabisa
Treatment and Care Programme, which uses a combin-
ation of a visual analogue scale, pill identification test and
pill count [31] and 2) an additional scale constructed to
limit both recall and social desirability bias and which has
been tested in different settings [32-34]. Quality of life will
be assessed using the Patient Reported Outcomes Quality
Of Life specific to HIV (PROQOL-HIV) [35,36] and the
HIV/AIDS stigma instrument for PLWHA (HASI-P) [37].
To assess drug resistance, HIV-1 genotypic resistance
testing will be performed for HIV-infected individuals
identified with virological failure during the trial, HIV-
infected individuals already on ART at trial entry and
identified with virological failure at enrolment and all
participants who seroconvert within the trial. We will
analyse all virological sequences using a phylodynamics
framework. Phylodynamics can be used to estimate the
date of origin of epidemiologically important events such
as the introduction of a new viral strain in a geograph-
ical area and identification of transmission networks
within and between clusters.
Analysis
The primary outcome is incidence of HIV-1 infection,
measured using DBS collected during home-based HCT,
and defined by seroconversion from negative to positive
between HCT rounds. An intention-to-treat analysis based
on the randomised clusters will be conducted for this pri-
mary trial outcome. Incidence rates per 100 person-years
will be calculated for the whole follow-up period. Adjusted
HIV incidence rate ratios in the intervention group relative
to the control group will be based on a multi-level Poisson
regression taking into account the intra-cluster correlation
and the repeated measurements when needed.
We will perform analyses using cluster-level approaches
as robustness analyses for checking consistency of the
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(including random effects) for the main outcome (HIV
incidence) and logistic regression with the generalised
estimated equation (GEE) approach for binary outcomes,
thus allowing for both levels (individual and cluster levels)
with easy adjustment for confounding factors [38]. As the
method does not perform well for a low number of
clusters, we plan to use the correction (of the sandwich
estimator and statistics distribution i.e. t-distribution)
proposed by Mancl and Derouen [39], which is particu-
larly appropriate when the cluster size does not vary.
Because of the possibility that the randomisation may
lead to some imbalance in the distribution of HIV risk
factors across the trial arms, an adjustment for baseline
characteristics known to be associated with HIV trans-
mission risk in this population will be undertaken. These
include HIV prevalence of the cluster, age, sex, marital
status, education level attained and migration status.
With regard to the randomisation, strata will be de-
fined on the basis of predicted HIV prevalence. Clusters
will be stratified according to 5% prevalence intervals
(<15, 15 to 20, 20 to 25, >25). With regard to the sample
size calculation, clustering was taken into account by the
coefficient of variation (0.25), the value of which was
based on the values used in other randomised trials in
Africa with HIV incidence as the outcome measure [27].
This coefficient of variation is necessarily conservative.
For instance, a coefficient of variation of 0.2 would have
led to the need for a population of 30,000 (24 clusters).
Through stratifying on the basis of estimated HIV preva-
lence we expect to minimize inter-arm variation in HIV
incidence. The sample size calculation is very conser-
vative and will be further adjusted on the basis of the
results of the first phase of the trial. In addition, the
extensive data related to population movements and
partnership patterns that will be collected over the course
of the trial will be used in a parallel set of secondary ana-
lyses to identify risk factors that influenced the risk of
transmission. If the intervention does not have a signifi-
cant impact, these important analyses will help to identify
which factors were likely to have led to the trial result.
Criteria for continuation/discontinuation at the end of the
first phase
The following criteria would be grounds for not continu-
ing from the first to the second phase. Feasibility: clear
indication that given the parameters measured during
the first phase (HIV prevalence in the clusters at base-
line and assessment of incidence; initial HIV testing
uptake; repeated HIV testing uptake; ART uptake; migra-
tion and the extent of sexual partnerships with people
outside the trial setting), the TasP trial will lack the statis-
tical power to detect significant HIV incidence differ-
ences between the intervention and control communities.Acceptability: clear indication from the clinic-based survey
and the qualitative in-depth interviews conducted during
the first phase that the TasP approach is not acceptable in
our setting, in terms of community attitudes and beliefs
about HIV, HIV counselling and testing, stigma and dis-
closure, participation in the TasP trial, and the accept-
ability of ART for the benefit of other community members.
The DSMB (see Additional file 1) will be able to con-
sider additional parameters measured during the first
phase, such as tuberculosis incidence, or information
from other studies.
Discussion
Two meta-analyses of observational studies [40,41] and a
recently concluded randomised controlled trial [4] pro-
vided evidence that antiretroviral treatment is effective in
preventing sexual transmission of HIV from the index
partner to the uninfected one. ART is now recommended
by the WHO to prevent HIV transmission in sero-dis-
cordant couples irrespective of whether the index partner
requires ART for their own health or not [42]. However,
the question remains whether the effectiveness of ART in
preventing transmissions at the individual level can be
replicated at the population level.
A population-based cohort study conducted by the Africa
Centre team examined the impact of ART coverage on HIV
incidence at the population level [5]. This study showed a
decrease in the risk of HIV acquisition when ART coverage
in the immediately surrounding area exceeds 20% of the
HIV-infected population. The authors recommended that
cluster randomised trials at population level are needed to
confirm the validity and generalizability of their findings.
Randomised controlled trials are the gold standard for
establishing the efficacy of a health intervention. Evaluat-
ing the impact of the TasP package of services on HIV
incidence does not focus on the HIV-infected individuals
who receive the intervention, but rather their HIV-unin-
fected sexual contacts. Had we opted for conventional
individual randomization of individuals, it would have
necessitated tracing all their sexual contacts, an option
which is not realistic in this setting. A less sophisticated
approach would have consisted of a simple comparison
of HIV incidence, before and after expansion of an ART
programme, similar in approach to the recent paper
from our group. However, many other factors besides
introduction of ART may change from "before" to "after",
introducing bias and incorrect attributions of causality
to any observed change in incidence. Hence we have
adopted a cluster-randomised trial approach as the best
design to examine the effectiveness of the TasP interven-
tion in reducing HIV incidence at the population level.
Within the TasP trial, HIV-infected patients residing in
the intervention clusters are encouraged to start ART ir-
respective of their CD4 count level; current SA eligibility
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threshold of 350 cells/µL or below. However, increas-
ingly treatment guidelines are moving towards earlier
initiation of therapy [43], which is driven predominantly
by evidence from observational studies.
The development of HIV drug resistant strains is a con-
cern in situations where treatment is started at higher
CD4 count thresholds, as in the case of ART as preven-
tion, since people will be on HIV treatment for longer with
increased potential for of sub-optimal adherence. Some
studies have shown that adherence is lower in individuals
starting ART at higher CD4 counts [44,45]. However, lim-
ited available data do not suggest an increased risk of drug
resistance with earlier HIV treatment [46]. Our trial will
be a valuable addition to knowledge in this regard.
In the TasP trial, quantitative and qualitative social sci-
ence research is implemented at each stage to inform un-
derstanding of the social determinants of the intervention,
uptake at the individual and community-level, and the so-
cial, economic and behavioural consequences at individ-
ual, household and community level. However, such social
science evidence alone cannot guide decisions on scaling-
up TasP strategies in public health programmes. If TasP is
demonstrated to be efficacious, new questions will need to
be addressed to inform public health and operational pol-
icies. These questions fall under three broad headings:
firstly, what are the social and behavioural consequences
of large numbers of people knowing their HIV-status and
potentially beginning ART early? Will the impacts on sex-
ual behaviour, disclosure and stigma be positive or harmful
both in the short term and in the long term? What will be
the impact on marginalised key populations? Secondly,
does seeing more healthy people with HIV attending
clinics alter community perceptions of disease and care,
and if that is the case, can salient positive changes be iden-
tified and replicated in other settings? Thirdly, what are the
operational and ethical implications of transforming re-
search interventions into routine care? What are the re-
quirements for sustainability? Which new ethical guidelines
will be needed to protect the most vulnerable populations?
Our trial documenting very important issues such as
HIV testing uptake, linkage to care, retention in care
and adherence to therapy and the social context in
which these occur will provide valuable information
about the feasibility and acceptability of universal initi-
ation of ART both for individual and public health bene-
fits. Cost effectiveness data will also inform decisions on
whether and how to take such strategies to scale or to
invest in existing proven cost-effective interventions
such as male medical circumcision and expanding cover-
age at current ART initiation thresholds [47]. There is a
window of opportunity to try and provide answers to
these important questions before clinical practice over-
takes evidence-based policy.Trial oversight
The Steering Committee (SC) will be responsible for the
conduct of the trial and its overall organization. The SC
is the trial decision body, for all scientific and adminis-
trative aspects. The SC will be co-chaired by the Principal
Investigators. It will comprise the team investigators in
South Africa, France and Switzerland and representatives
of the Sponsor. The SC will meet as regularly as needed
on conference calls and face-to-face meetings. The SC
ensures the correct implementation of the study and
compliance with the protocol, and verifies its ethical com-
pliance. It decides about any relevant changes to the proto-
col, necessary for continuation of the study.
The Scientific Advisory Board (see Additional file 1)
would oversee the overall conduct of the trial. Its mission
is to make sure and to report, particularly to the Sponsor,
whether the study is carried out properly scientifically,
ethically and logistically.
The DSMB would monitor the main safety and efficacy
outcome measures and the overall conduct of the trial,
with the aim of protecting the safety and the interests of
the trial participants. The DSMB would meet on a regular
basis during the trial and at least once a year.
Ethical safeguards
This trial was approved by the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal on 2 Febru-
ary 2012 for the control clusters and on 6 July 2012 for the
full trial. The trial is being conducted with the permission
of the KwaZulu-Natal DoH, South Africa. Permission by
the South African Medicines Control Council was granted
on 28 June 2012. Consent for the collection of data and the
retention of residual samples will be solicited from individ-
uals following established procedures in the Africa Centre
surveillance, and approved by the University of KwaZulu-
Natal Biomedical Research Ethics Committee.
Routine community road shows will be used to ensure
continuous feedback between the investigators and the
communities.
Trial status
The trial started enrolling participants in March 2012.
Additional file
Additional file 1: Table S1. Composition of the TasP Study Group.
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